Disclosure: I am here for the Patents plural and

New Post Public Reply Private Reply Replies (0) Message Board

Mar 22, 2013 at 9:37 PM

Disclosure: I am here for the Patents plural and intellectual property rights related to Eli 216 and 154 and the real money garnered in relation to them. Still 2-4 years away IMO but quickly becoming much more of a reality as opposed to my first purchased shares in 2011. It has been more than a painful ride. In my further opinion, there has been no better time than these past few months to purchase shares in relation to what the company is doing related to their pipeline. Elite has the technology to more than challenge Purdue and Pfizer in the Abuse Resistant Opioid space.

There used to be 6 Abuse Resistant Products on the market.....NOW there are only 5 as Pfizer has been unable to rectify Embedas stability issues.

1) Suboxone
2) Oxycontin
3) Opana
4) Oxecta
5) Exalgo

6) Embeda (Whoops)

Now out of those 5 Abuse Resistant Opioids on the market...........Actavis has rights to the generic version of every single one of those above products EXCEPT Embeda.....and if you know anything about the history between Pfizer and Actavis related to Embeda....you realize the only place Actavis is going to get the rights to its own version of Embeda is for Elite to build Actavis a better Embeda.....which it is doing IMO via Mik001. The other possibility I see is a Hydromorphone/Naltrexone product....but I hope for Elite's sake Mik001 is a Better Embeda and not a Hydro /Nal product. My conclusion related to the latter will become clear below.

Once you begin to understand the magnitude of a company like Actavis needing to come to Elite to get in on a product that it cannot make itself you begin to get even an inkling of the Abuse Resistant technology (ART) that Elite owns itself outright. And note that Actavis came to Elite for Embeda before Elite garnered the patents on the very technology that Elite is using to make that better Embeda.

Now it is true that Elite had best keep moving forward on their Abuse Resistant Drugs! Should the FDA and/or Congress mandate new opioid formulations to carry abuse deterrent properties the already competitive Abuse REsistant space will do nothing but heat up and heat up quickly for that matter IMO. Still, Elite will be sitting pretty in one of only a few catbird seats regarding many generic companies needing to license abuse deterrent technology as they won't have the time or money to create their own technologies and yet these companies will still wish to compete in the multi billion dollar abuse deterrent opioid space. They will only have so many choices in regards to licensing this abuse deterrent technology from pharmaceutical companies that already own their own abuse deterrent technology such as Elite owns.

Then you take what JT has already publicly mentioned regarding his personal goal......to put out a whole line of Abuse Resistant Opioids with their patented technology. One possibility would be to put out a Branded Abuse Resistant product such as Embeda but say with Hydromorphone/Naltrexone. As far as I can tell there isn't a product of this combination on the market currently.

How would a company like Actavis then obtain the generic rights to this Branded Hydromorphone/Naltrexone product as the company plans to own the generic rights to as many abuse resistant opioids as it can obviously ???

If the FDA moves in the fashion it looks like it will be heading.....Actavis would only be able to submit little of Elite's data as the reference listed drug to Actavis's Hydro/Nal Anda submission.....bc Elite will have used Patented technology for this NDA drug. Even if Elite wanted to let Actavis use their reference listed drug data.....the FDA wouldn't let Actavis as Actavis would need to license Elite's technology or come up with their own Abuse Deterrent technology and then see what the FDA would say about doing so?? What the FDA would do in the latter scenario is yet unknown but has significant positive financial bearing on Elite no matter how the FDA decides down the road on the matter IMO.

I realize Elite has the capability of making their Eli 216 product itself....within that Billion Dollar space......that is a Game Changer in and of itself for Elite.....but when you consider Elite's Intellectual Property rights potential for their patented Abuse REsistant technology (ART) and the possibilities become absolutely staggering! This staggering possibility is when you begin to realize that shares bought now have the real potential to set one up for a really nice retirement.

***** These are solely my opinions and have come to me over considerable time through my own hard fought due diligence on the company....do not buy shares on my opinions. Do your own DD and make up your own mind related to ELTP. Good luck to you and if you have questions ask. I am happy to say this board has many savvy traders and investors well beyond my years.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbsenceSoft's AI Leave Planner Tackles HR Headaches

Pioneering Technology in Leave Management AbsenceSoft is rolling out a tool that's about to shake up the HR world in a big way. MyAbsence, powered by AbsenceSoftAI, seems ready to cut down on the common confusions that send HR folks spinning around like they're in a two-step dance competition, juggling leave requests and compliance checks. It's all about getting the...

Systemair Wins First Natural Refrigerant Heat Pump Deal

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...

Natuvion and PwC's IT Roadbook: A Game-Changer?

IT Transformations: A Tough Nut to Crack Transforming IT systems isn't just about plugging in new tech. It's a beast of a task, fraught with pitfalls and peopled with ambitious project managers hoping to dodge them. Natuvion and PricewaterhouseCoopers (PwC) have put together a book that could be the guide folks need when wading into these complex waters. The 'Why' of...

Harbour BioMed's Strategic Nudge with Vivian Feng Hire

A Refreshing Jolt for Harbour BioMed's Growth Journey Harbour BioMed just threw down a new card by bringing in Ms. Vivian Feng as the Senior Vice President, Head of External Collaboration. There's a real sense of drive coming from this decision. When a biopharma outfit asserts its intent to ramp up growth, and they hang the hat on someone like Vivian, you better believe...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

Cincoro Tequila Unveils Rare Añejo for Holidays

Firing Up the Holiday Spirit with Cincoro Well, isn't this a timely toast to class? As if the tequila scene wasn't already brimming with options, Cincoro's decided to paint the town gold with a rare addition to its lineup. For those of you who treat your liquor collection like a stockpile of fine art, here's something that'll turn heads this holiday season—the Añejo...

Charming Holiday Inflatables Add Festive Flair

Small Spaces, Big Holiday Spirit Not everyone’s got the sprawling front yard of a mansion to decorate, but that doesn’t mean you have to miss out on holiday cheer. Gemmy’s latest pint-sized holiday inflatables hit the market this season, aiming straight for those of us with cozy porches and snug apartments. These little guys might measure only 3 to 5 feet tall, but...

Ophthalmic Equipment Market Set for Growth Surge by 2031

Eyeing the Road Ahead: Vital Market Growth Insights We've got ourselves a sector on the move. The ophthalmic equipment market, pegged at USD 21.2 billion in 2026, is set to climb up to a whopping USD 30.5 billion by 2031. Knowing that it’s growing at a steady clip of 7.5% CAGR over these years, there’s more than just a glimmer of opportunity for those savvy enough to...

RingConn Joins BVB Women's Team: Tech Meets Sport

Tech and Football: An Unlikely Alliance Alright, so here's a story that might perk your ears up—RingConn, a relative newcomer in the health tech world, has chosen to stake its future on a bet with Borussia Dortmund's women's football team. This isn't just your average brand-sponsorship slap-on-the-shirt deal; we're looking at a potential game-changer here, folks. Who...

Bluevua Triumphs with Three BASA Awards Wins

Bluevua Sweeps the 2026 BASA Awards Stacking accolades like old trading wins, Bluevua just clinched not one, not two, but three 2026 Best of America Small Business Awards (BASA Awards®). If that's not a feather in their cap, I don't know what is. For the uninitiated, these BASA nods are no small potatoes—they're like the Oscars for small businesses. Bluevua, known for...